Serum Institute of India, Ltd.

27 articles with Serum Institute of India, Ltd.

• Serum Institute Selects ABEC for Large-Scale, Single-Use COVID-19 Vaccine Manufacturing

  9/30/2020

  ABEC , a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced it is supporting Serum Institute of India Pvt. Ltd. (SIIPL) in Pune, India by delivering six 4,000L CSR bioreactors for the manufacturing of Novavax’ COVID-19 vaccine can

• 

  New Collab Boosts Serum Institute of India’s COVID-19 Vaccine Production by 100 Million Doses

  9/30/2020

  The Serum Institute of India (SII) has agreed to produce and deliver up to an additional 100 million doses of an approved COVID-19 vaccine for citizens of India and neighboring low- and middle-income countries as part of a collaboration with Gavi and the Bill & Melinda Gates Foundation.

• Serum Institute of India Initiates Manufacturing of Codagenix's Intranasal Live-Attenuated COVID-19 Vaccine Candidate

  9/22/2020

  - Phase 1 clinical trial of CDX-005 expected to initiate prior to year-end 2020 - Serum Institute to ramp-up manufacturing for large-scale safety and efficacy studies and to meet global vaccine supply requirements   [22-September-2020]   FARMINGDALE, N.Y. , Sept. 22, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing pr

• 

  Biopharma Update on the Novel Coronavirus: September 16

  9/16/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
• 

  Widespread Distribution of a COVID-19 Vaccine Could Take As Long as 2024

  9/15/2020

  Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.
• 

  Novavax Doubles COVID-19 Vaccine Manufacturing Capacity with SIPL Agreement

  9/15/2020

  Novavax and Serum Institute of India Private Limited (SIIPL) amended an agreement struck last month that will allow the company to double the number of doses of its experimental COVID-19 vaccine for potential use in 2021.

• Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually

  9/15/2020

  Novavax, Inc. announced an amendment to its existing agreement with Serum Institute of India Private Limited under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate.

• SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

  9/8/2020

  SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, announces that its partner the Serum Institute of India has dosed the first subjects in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19.

• Novavax and Serum Institute of India Announce Development and Commercial Collaboration

  8/6/2020

  Expected to support minimum of 1 billion doses of NVX-CoV2373 for India and low- and middle-income countries

• Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

  3/11/2020

  Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University Phase 2b clinical efficacy study

• Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19

  2/13/2020

  FARMINGDALE, N.Y. , Feb. 13, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the emergent coronavirus. There are no licensed vaccines or therapeutics for this nov

• Serum Institute and Aragen Bioscience Announce Collaboration on Vaccine Development

  1/8/2020

  Aragen Bioscience, Inc and Serum Institute of India Pvt. Ltd. are pleased to announce a collaboration for the development of multiple stable cell lines to support Serum’s HIV program.

• Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology

  9/30/2019

  Aridis Pharmaceuticals, Inc. announced that it has consummated a licensing agreement with Serum AMR, an affiliate of Serum International BV and the Serum Institute of India, Ltd.

• Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology

  7/30/2019

  Aridis Pharmaceuticals, Inc. announced that it has entered into an option agreement with the Serum International BV, an affiliate of Serum Institute of India, Ltd., the world's largest vaccine manufacturer by dose units.

• Ascenion’s Portfolio Company VPM Acquired by SII

  8/21/2018

  Ascenion GmbH, the technology transfer partner of the Helmholtz Institute for Infection Research (HZI), has successfully negotiated the trade sale of the HZI spin-off Vakzine Projekt Management GmbH (VPM) to its longstanding partner, Serum Institute of India Pvt. Ltd (SII), in an all-cash deal.

• Historic Deal Signed Between Panacea Biotec and Serum Institute of India

  1/19/2018

  Under the collaboration, SII is entitled to manufacture and sell fully liquid wP and Salk based IPV based Hexavalent vaccine developed and commercialized by PBL.

• Genticel Successfully Completes Determining Milestone In Partnership With Serum Institute of India, Ltd. Regarding Use Of GTL003 In Multivalent Vaccines

  12/1/2016

• Serum Institute of India, Ltd. in Stake Sale Talks at $12 Billion Valuation

  9/18/2015

• Visterra, Inc. And Serum Institute of India, Ltd. Announce Collaboration To Advance VIS513, A Monoclonal Antibody In Development For The Treatment Of Dengue, In The Indian Subcontinent

  9/9/2015

• Genticel Licenses Vaxiclase Platform To Serum Institute of India, Ltd. For Use In Pertussis Vaccines

  2/2/2015